**Aims & Scope:**
The proposed research investigates the general and context-dependent mechanisms of COVID-19 infection both before and after it in human and will explore the COVID-19 association with T2D and/or cancer(s). Further, it provides the potential herbal drugs and their possible and promising and potential targets in common or individually for the purpose to diagnose and treat. With global and rapidly growing concern and highly dangerous to human health, it appears that there is an urgent need to understand the proper mechanism of coronavirus infection and its impact after infection to the biological mechanisms, pathways, and the functions within the cell of the infected person. To date, it has been understood and clear that it potentially affects the immune, infection, and inflammatory systems leading to the **hypothesis** that the immune and inflammatory systems (signaling pathways and the components) fail to control the infection and opens the window to look for possible targets mainly from these systems only. In this study, we will mainly focus on the plant extracts to target coronavirus infection and will be focusing on to finding the possible herbal drug targets and pathways in case of human coronavirus infection, cancers and type 2 diabetes.

**Keywords:** Coronavirus, type 2 diabetes, cancers, gene expression and docking profiling, pathological biomarkers, infection and immune system, differentially expressed genes network.

**Subtopics:**
The sub-topics to be covered within the issue should be provided:

- COVID-19 candidate genes and pathways and its association with lung cancer
- potential signaling molecules to target COVID-19 which mediates pancreatic cancer
- COVID-19 immune system associated genes and the potential linkage with type-2 diabetes
- Understanding the role of GSK3B to cross-link COVID-19, type-2 diabetes, and melanoma
- Cell cycle and its impact on COVID-19, diabetes, and cancer
- Functional impact of DNA damage-repair in cancer, diabetes, and/or COVID-19

**Schedule:**
- Manuscript submission deadline: December 15, 2020
- Peer Review Due: December 31, 2020
- Revision Due: January 15, 2021
- Announcement of acceptance by the Guest Editors: January 31, 2021
- Final manuscripts due: February 15, 2021

**Contacts:**
- **Guest Editor Name:** Dr. Mohammad Mobashir and Professor Dr. Mohammad Amjad Kamal
- **Affiliation:** Department of Microbiology, Tumor and Cell Biology
  Karolinska Institute, Stockholm, Sweden
- **Email:** m.mobashir@cdslifesciences.com
Guest Editor Name: Professor Dr. Mohammad Amjad Kamal

Affiliation: Distinguish Adjunct Professor
King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia

Email: prof.ma.kamal@gmail.com

Any queries should be addressed to ctmc@benthamscience.net.